Eloxx Posts Quarterly Loss of $0.49 per Share as Net Loss Widens
Key Facts
Eloxx Pharmaceuticals reported on November 16 results for the third quarter ended September 30, 2026, posting a net loss of $0.49 per share, compared with a loss of $0.58 in the same period of 2025. Quarterly net loss was $5.543 million, versus $351,000 a year earlier, meaning the overall loss widened despite an improvement in loss per share. The company’s filing with the U.S. Securities and Exchange Commission confirmed these figures. The company said cash and cash equivalents totaled $56.3 million at the end of September, compared with $62.0 million at the end of June. It said its current cash resources are sufficient to fund operations through 2028.
The differing movements in net loss and loss per share reflect a wider overall loss in the quarter alongside a lower loss calculated per share than in the comparable period. For the first nine months of 2026, net loss was $13.799 million, or $1.83 per share, compared with $3.951 million and $9.12 per share in the first nine months of 2025. The statements also showed research and development expenses rising to $4.0 million in the quarter, from a net credit balance of $0.3 million a year earlier. The company attributed the increase mainly to clinical trial expenses following the start of the EXACT study and higher personnel costs. General and administrative expenses rose to $1.9 million from $0.5 million in the third quarter of 2025, with increases in professional and consulting fees, personnel costs, facilities and general expenses.
The company’s clinical activities are focused on rare kidney disease programs. Chief Executive Sumit Aggarwal said the company had dosed the first two patients in the Phase 2b EXACT study, which targets Alport syndrome associated with nonsense mutations. He added that the EXPRESS protocol had been completed and received IND clearance, describing this as placing two of the company’s programs in rare kidney diseases. EXACT plans to enroll 24 patients, with the first part including 16 weeks controlled by placebo. The company expects preliminary data from this part in mid-2027, followed by final data at 32 weeks by the end of 2027.
EXPRESS, meanwhile, is a planned global trial of about 60 adults, randomized 1:1 between exaluren and placebo for 52 weeks. The company expects to dose the first patient in the third quarter of 2027 and publish preliminary 52-week data in the first half of 2029. It said the U.S. Food and Drug Administration’s pre-meeting responses indicated that a substantial and sustained treatment effect could potentially form the basis for a request for breakthrough therapy designation. It said any such designation would depend on trial results and subsequent discussions with the agency. These timelines put upcoming clinical results at the center of the company’s path after it said current liquidity would fund operations through 2028.
The company remains dependent on financing as it develops its clinical candidates. In its filing, it said it had generated no revenue from the sale of products or services, except for licensing and service revenue related to its agreement with Almirall. It added that it does not expect significant revenue unless its candidates in development receive marketing approval and are commercialized. The accumulated deficit was $314.4 million on September 30, 2026, and the company expects net losses and negative operating cash flows to continue for the foreseeable future. In June, it completed a public offering that generated net proceeds of $58.3 million, alongside the transfer of its stock listing to the Nasdaq Capital Market. ELOX shares closed at $13.15 on November 13, a closing price before the results announcement on November 16.